Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858412 | 0.92 | MITF (0.31) | MAPT | |
| SCHEMBL5859232 | 0.89 | NAMPT (0.31) | — | |
| SCHEMBL5857877 | 0.88 | CA12 (0.33) | MAPTSMN1; SMN2 | |
| SCHEMBL5858270 | 0.88 | RXFP1 (0.37) | NOTUMTP53MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL5856885 | 0.87 | BACE1 (0.34) | BACE1PDGFRB | |
| SCHEMBL3940647 | 0.86 | BACE1 (0.35) | BACE1PDGFRBNOTUMBRD4TP53 | |
| SCHEMBL5859382 | 0.84 | NOTUM (0.36) | NOTUMTP53SMN1; SMN2 | |
| SCHEMBL3935527 | 0.83 | AAK1 (0.40) | BACE1PDGFRB | |
| SCHEMBL4488531 | 0.83 | BACE1 (0.41) | BACE1PDGFRBNOTUMBRD4TP53 | |
| SCHEMBL4500074 | 0.83 | BACE1 (0.38) | BACE1PDGFRBNOTUMBRD4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148249-B2 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | BACE1 1424/4885PDGFRB 609/4885NOTUM 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.